ABSTRACT FROM: Zheng W, Xiang YT, Xiang YQ, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand 2016;134:385–98.
Although a previous meta-analysis showed that topiramate-antipsychotic cotreatment improved the psychopathology and prevented/reduced weight gain in patients with schizophrenia,1 the number of patients and studies included in the analysis were small (8 randomised controlled trials (RCTs), 439 patients). Therefore, Zheng et al conducted a systematic review and meta-analysis to achieve more robust evidence with respect to the efficacy for psychopathology and body weight of topiramate adjunctive therapy in antipsychotic-treated schizophrenia (16 RCTs, 934 patients). To read the full article, log in using your NHS OpenAthens details.